Three-Year Data Confirm Revi’s Unmatched Durability and Patient Satisfaction
Why is the treatment of urgency urinary incontinence (UUI) still a significant challenge for healthcare providers? BlueWind Medical, a leader in Implantable Tibial Neuromodulation (ITNM), has introduced the Revi® System, a patient-centric solution designed to address UUI. The company recently announced three-year results from the pivotal OASIS study, which were presented by Dr. Roger Dmochowski, Chief Medical Officer of BlueWind Medical, at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2026 Winter Meeting. The data confirm Revi’s sustained efficacy, excellent safety, and exceptional patient satisfaction, solidifying its position as the most clinically validated ITNM therapy for UUI.
Key Insights at a Glance
- Patient Satisfaction: 95% of patients reported therapeutic satisfaction at 36 months.
- Durable Efficacy: Therapeutic effectiveness maintained from 6 to 36 months.
- High Responder Rate: 79% of participants were therapy responders.
- Symptom Reduction: 63% of patients experienced a ≥75% reduction in UUI episodes.
The Persistent Challenge of UUI Treatment
Urgency urinary incontinence (UUI) affects millions of women, significantly impacting their quality of life. Traditional treatments often come with limitations, such as low patient compliance and high complication rates. The OASIS study, involving 151 adult women, highlights the critical need for a durable, effective, and minimally invasive solution. The study’s findings, showing a 95% patient satisfaction rate and a 79% therapy responder rate, underscore the urgency of addressing this issue with innovative technologies like the Revi® System.
A Fresh Approach to Long-Term Efficacy
Just as a well-constructed foundation ensures the longevity of a building, the Revi® System’s design ensures long-term therapeutic benefits for UUI patients. The study’s three-year data reveal consistent and significant reductions in UUI episodes and nocturia, with no device- or procedure-related serious adverse events reported. This robust safety profile and high patient satisfaction rate demonstrate that BlueWind Medical’s approach is not only effective but also sustainable, setting a new benchmark in ITNM.
BlueWind Medical’s Innovative Solution
BlueWind Medical has developed the Revi® System, an Implantable Tibial Neuromodulation (ITNM) device designed to treat urgency urinary incontinence (UUI). The device is implanted near the ankle in a single outpatient procedure under local anesthesia, delivering targeted stimulation to the posterior tibial nerve via a lightweight, external wearable. This innovative design allows patients to activate therapy once daily at home, avoiding complications such as lead fracture, migration, or battery depletion. Dr. Dmochowski stated, “With the most comprehensive and longest-term data in Implantable Tibial Neuromodulation, BlueWind has set a new benchmark for durable, patient-centered therapy for UUI.”
Future Outlook
The future of UUI treatment is evolving, and BlueWind Medical is at the forefront. The company’s commitment to enhancing patient quality of life and overall well-being is evident in the Revi® System’s success. As the only ITNM device to receive FDA clearance for UUI, Revi is poised to continue leading the way in minimally invasive, patient-centric solutions. The next milestone for BlueWind Medical is to expand the clinical evidence base and explore new applications for ITNM.
Conclusion
The announcement of the OASIS study’s three-year results marks a significant advancement in the treatment of urgency urinary incontinence. For healthcare providers and patients, this means a more reliable, effective, and patient-friendly solution. How is your practice preparing to integrate this innovative technology? Join the conversation in the comments below.
About the Revi® System
Revi® is an innovative Implantable Tibial Neuromodulation (ITNM) device designed for the treatment of urgency urinary incontinence (UUI). Implanted near the ankle in a single outpatient procedure under local anesthesia, Revi delivers targeted stimulation to the posterior tibial nerve via a lightweight, external wearable. This design offers patients a simple, durable, and effective long-term solution for UUI symptom relief. Patients activate therapy once daily at home, without the need for internal batteries or leads, avoiding complications such as lead fracture, migration, or battery depletion.
About BlueWind Medical Ltd.
BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urgency urinary incontinence (UUI). BlueWind’s Revi® System is the first and only Implantable Tibial Neuromodulation (ITNM) device activated by a battery-operated external wearable to receive FDA clearance for the treatment of patients with UUI. Revi is the only neuromodulation therapy on the market that allows physicians to use their discretion to determine whether the patient should fail or not tolerate more conservative treatments before using the Revi System, rather than mandating “step-therapy.
Source link: https://www.businesswire.com/
